Evidence map›Paper›PMID 35046575›Full record

ArticleNature structural & molecular biology2022

Can AlphaFold2 predict the impact of missense mutations on structure?

Gwen R Buel, Kylie J Walters

Abstract readLetter
In one paragraph

Article in Nature structural & molecular biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 208 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
208citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

208 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Targeting p53 pathways: mechanisms, structures, and advances in therapy.Signal transduction and targeted therapy · 2023
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Emergence Biases in Molecular Evolution.Genome biology and evolution · 2026
    Review
  9. Article
  10. Article
  11. Ensembles ofbioRxiv : the preprint server for biology · 2026
    Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Limitations of the refolding pipeline for de novo protein design.Protein science : a publication of the Protein Society · 2026
    Article
  18. Review
  19. Article
  20. Article

148 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gwen R BuelCenter for Structural Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.ORCID http://orcid.org/0000-0003-2917-3055
Kylie J WaltersCenter for Structural Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA. kylie.walters@nih.gov.ORCID http://orcid.org/0000-0001-7590-2891

Funding

Myosin VI: a new ubiquitin receptorZIABC011627 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WALTERS, KYLIE · 2015 to 2025
$4.6M
Intramural NIH HHS ZIA BC011627
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AlgorithmsModels, MolecularMutation, MissenseProtein DomainsProteinsProtein Structure, SecondaryUbiquitinProteinsUbiquitin

Identifiers

PMID35046575
PMCPMC11218004

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.